Navigation Links
Angiotech Pharmaceuticals Announces Conference Call and Webcast
Date:6/24/2010

Second Quarter 2010 Financial Results

VANCOUVER, June 24 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) will host a conference call discussing its financial results for the second quarter ended June 30, 2010, on Friday, July 30, 2010 at 11:00 AM ET (8:00 AM PT).

Dial-in information for the earnings call on July 30, 2010 is as follows:

    North America (toll-free): (866) 277-1182
    International: (617) 597-5359
    Enter Passcode: 18173223

A live webcast of the earnings call will be available to interested parties through Angiotech's website at www.angiotech.com in the Investors section.

A press release announcing Angiotech's financial results will be issued prior to the call on July 30th at approximately 8:00 AM ET (5:00 AM PT).

An archived replay of the call will be available until August 6, 2010.

Replay information is as follows:

    North America (toll-free): (888) 286-8010
    International: (617) 801-6888
    Enter Passcode: 33507758

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company. Angiotech discovers, deve
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
2. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
3. Angiotech Pharmaceuticals Announces Conference Call and Webcast
4. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
5. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
6. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
7. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
9. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
10. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
11. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Alba Therapeutics Corporation today,announced that its Investigational New ... endogenous insulin production capacity in new-onset,type 1 diabetes ... period,by the U.S. Food and Drug Administration (FDA). ... in 2008 while focusing the majority,of its development ...
... Sept. 5 Thermo Fisher,Scientific Inc. (NYSE: ... has,acquired the instrument sales business of Davis Inotek ... Instruments and excludes its,related calibration services. Davis Instruments ... control instruments, serving customers in a,wide range of ...
... A study in the August 2007,issue of ... GlycoMark,1,5-anhydroglucitol (1,5-AG) blood test to evaluate therapy ... hyperglycemia (elevated,after-meal glucose levels). Controlling after-meal glucose ... and reducing the burden of,cardiovascular complications, the ...
Cached Biology Technology:Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001 2Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 2Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 3Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 4Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes 2
(Date:7/9/2014)... one of the amphibians with the highest distribution in ... of water where it comes into contact with the ... carried out by the Spaniard Germn Orizaola from the ... these frogs have developed a defensive response to the ... bodies if they co-exist with the crayfish. , Numerous ...
(Date:7/9/2014)... increase the survival rate of naturally aged animals? ... Pharmaceutical Sciences, Southwest University, China performed an animal ... low dose of levothyroxine for 3 consecutive months. ... obvious improvement in cognitive and an increased rat ... mechanism was demonstrated that levothyroxine treatment can increase ...
(Date:7/9/2014)... cancer patients with high levels of vitamin D in their ... shows. , Patients with the highest levels of vitamin ... with the lowest levels, the findings reveal. , The study ... D in bowel cancer patients after their diagnosis which ... from dietary sources with their long term survival prospects. ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3
... Mental Health (CAMH) is proud to announce a landmark ... Innovation (CFI) into research that will propel the understanding, ... to the next level of excellence. This ... Research Hospital Fund will allow CAMH to leverage our ...
... new study in the September issue of the Journal ... may have a role in the rising rate of diabetes, ... , DNA is the primary mechanism of inheritance; kids get ... scientists are just starting to understand additional kinds of inheritance ...
... invasion of unwanted species, according to a recent U.S. ... the reef and eliminate all the native coral, dramatically ... This study documents for the first time that a ... reef is unambiguously associated with man-made structures. ...
Cached Biology News:Large-scale investment catapults CAMH's mental illness and addiction research forward 2Shipwrecks on coral reefs harbor unwanted species 2
Recombinant Equine IL-6...
... Checker Kits provide two highly efficient methods ... time-consuming plasmid preparation. By using the large-scale ... need to do is to transfer partial ... the transformation plates into the solutions provided ...
... Butcher (1998). • The major histocompatibility complex ... the immunology area. There is great interest ... in their function as antigen-presenting molecules. Many ... prospect of tackling biochemical and genetic techniques ...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: